Table II.
Demographic, biochemical and redox profile of CAD patients that have developed early CIN.
| Parameters | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|---|---|---|---|
| Age (years) | 67 | 76 | 80 | 55 |
| Sex | Male | Female | Female | Male |
| Weight (Kg) | 74 | 70 | 73 | 98 |
| Height (cm) | 175 | 165 | 150 | 180 |
| BMI | 24.2 | 25.7 | 32.4 | 30.2 |
| Smoking | Ex-smoker | No | No | Yes |
| Chronic treatment | ||||
| Anti-platelets | Yes | Yes | Yes | Yes |
| Anti-coagulants | – | – | – | – |
| β-blockers | Yes | Yes | – | – |
| Ca channel blockers | – | – | – | Yes |
| ACE inhibitors | Yes | Yes | Yes | – |
| Diuretics | – | Yes | – | – |
| Statins - anti-lipidemics | Yes | Yes | Yes | Yes |
| Anti-diabetics | – | – | – | Yes |
| Laboratory data | ||||
| Hematocrit | 37.640.5 | 38.2 | – | |
| Hemoglobin | 12.313.3 | 12.5 | – | |
| P/L | 11672.4 | 119 | – | |
| N/L | 2.94 | 1.39 | 2.79 | – |
| Glucose (mg/dl) | 81 | 106 | 148 | 85 |
| Insulin | 20.2 | 18.5 | 21.6 | 61 |
| FIRI | 65.4 | 78.4 | 128 | 207 |
| Creatinine (mg/dl) | ||||
| t=0 | 0.59 | 0.45 | 0.50 | 0.68 |
| t=2 h | 0.89 | 0.68 | 0.65 | 0.98 |
| t=4–6 h | 0.85 | 0.80 | 0.68 | 1.06 |
| Urea (mg/dl) | ||||
| t=0 | 31 | 30 | 55 | 16 |
| t=2 h | 42 | 27 | 57 | 25 |
| t=4–6 h | 40 | 30 | 49 | 19 |
| Uric acid (mg/dl) | 5.40 | 4.10 | 3.90 | 4.40 |
| Cholesterol (mg/dl) | 148 | 194 | 182 | 132 |
| Triglycerides (mg/dl) | 132 | 140 | 122 | 152 |
| HDL (mg/dl) | 42 | 39 | 56 | 40 |
| LDL (mg/dl) | 100 | 116 | 108 | 122 |
| K (mmol/l) | 4.9 | 4.0 | 4.4 | – |
| Na (mmol/l) | 138 | 136 | 137 | – |
| Albumin (g/dl) | 44 | 36 | – | – |
| Total protein (g/dl) | 65.2 | 60.4 | – | – |
| SGOT (IU/l) | 19 | 18 | 14 | – |
| SGPT (IU/l) | 20 | 13 | 11 | – |
| γ-GT (IU/l) | – | 16 | – | – |
| LDH (IU/l) | – | 218 | – | – |
| CPK (U/l) | 59 | 135 | – | – |
| Oxidative stress markers | ||||
| GSH (µmol/g Hb) | ||||
| t=0 | 0.663 | 0.145 | 0.061 | 0.045 |
| t=2 h | 1.005 | 0.248 | 0.086 | 0.170 |
| t=4–6 h | 2.626 | 0.270 | 1.23 | 1.48 |
| TAC (mmol DPPH/L plasma) | ||||
| t=0 | 0.919 | 0.757 | 0.791 | 0.961 |
| t=2 h | 0.992 | 0.828 | 1.08 | 1.07 |
| t=4–6 h | 1.02 | 0.897 | 1.05 | 1.00 |
| TBARS (µmol/l) | ||||
| t=0 | 5.86 | 3.77 | 3.82 | 2.75 |
| t=2 h | 5.75 | 2.74 | 4.62 | 3.34 |
| t=4–6 h | 9.85 | 2.96 | 5.64 | 3.04 |
| Catalase (U/mg Hb) | ||||
| t=0 | 154 | 125 | 217 | 199 |
| t=2 h | 160 | 135 | 189 | 218 |
| t=4–6 h | 149 | 128 | 220 | 214 |
| Carbonyls (nmol/mg protein) | ||||
| t=0 | 0.826 | 1.02 | 0.779 | 1.64 |
| t=2 h | 0.816 | 0.765 | 0.861 | 0.715 |
| t=4–6 h | 0.824 | 0.983 | 0.746 | 0.586 |
ACE, angiotensin converting enzyme; BMI, body mass index, BMI, weight (kg)/(height)2 (m2); CAD, coronary artery disease; CT, computed tomography; CA, coronary angiography; ARB, angiotensin receptor blockers; N/L, neutrophils to lymphocytes ratio; P/L, platelets to lymphocytes ratio; CRP, C-reactive protein; FIRI, (glucose × insulin)/25; TAC, total anti-oxidant activity; GSH, glutathione; TBARS, thio-barbituric acid reactive species.